# Role of Liquid Phase Concentrated Growth Factors vs. Hypertonic Dextrose Prolotherapy for Management of Patients With Disc Displacement Without Reduction

> **NCT04557878** · PHASE2 · COMPLETED · sponsor: **Nourhan M.Aly** · enrollment: 24 (actual)

## Conditions studied

- Temporomandibular Joint Disorders
- Temporomandibular Disorder

## Interventions

- **DRUG:** Hypertonic Dextrose Solution
- **BIOLOGICAL:** Liquid Phase Concentrated Growth Factor (LPCGFs)

## Key facts

- **NCT ID:** NCT04557878
- **Lead sponsor:** Nourhan M.Aly
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-06
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557878, "Role of Liquid Phase Concentrated Growth Factors vs. Hypertonic Dextrose Prolotherapy for Management of Patients With Disc Displacement Without Reduction". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04557878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*